INTERNATIONAL STEM CELL CORPORATION (OTCMKTS:ISCO) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 Submission of Matters to a Vote of Security Holders
International Stem Cell Corporation (the “Company”) held its Annual Meeting of Stockholders on June 21, 2018. The stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement dated May 11, 2018.
|
Proposal1: |
Election of four directors to hold office until the 2019 Annual Meeting: |
|
A. |
Directors elected by holders of Series D Preferred Stock. |
|
FOR |
WITHHELD |
|
|
Andrey Semechkin |
2,457,142 |
|
|
Russell Kern |
2,457,142 |
|
B. |
Directors elected by holders of all shares of stock. |
|
FOR |
WITHHELD |
|
|
Donald A. Wright |
6,749,460 |
17,638 |
|
Paul V. Maier |
6,748,949 |
18,149 |
Broker Non-Votes: none
All of the foregoing candidates were elected.
|
Proposal2: |
Approval of amendments to the Company’s 2010 Equity Participation Plan: |
|
FOR |
AGAINST |
ABSTAIN |
|
6,728,762 |
35,137 |
3,199 |
Broker Non-Votes: none
The foregoing proposal was approved.
About INTERNATIONAL STEM CELL CORPORATION (OTCMKTS:ISCO)
International Stem Cell Corporation (ISCO) is a biotechnology company. The Company is focused on therapeutic and biomedical product development. The Company’s segments include Therapeutic Market, Cosmetic Market and Biomedical Market. The Company’s subsidiaries include International Stem Cell Corporation, a research and development company, for the Therapeutic Market for clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases, such as Parkinson’s disease, liver diseases and corneal blindness; Cyto Therapeutics, PTY LTD, a research and development company, for the Therapeutic Market; Lifeline Skin Care, Inc. for the Cosmetic Market, which develops, manufactures and markets a category of cosmetic skin care products based on biotechnology with human stem cells, and Lifeline Cell Technology, LLC for the Biomedical Market, which develops, manufactures and commercializes primary human cell research products.
